Literature DB >> 16394183

Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance.

Ding-Wu Shen1, Xing-Jie Liang, Toshihiro Suzuki, Michael M Gottesman.   

Abstract

Based on analyses of two-dimensional gel and cDNA microarrays, our laboratory and others have demonstrated that a number of genes show altered expression during the development of cisplatin resistance (CP-r) in human cancer cells, including genes associated with DNA damage repair, proto-oncogenes, apoptosis, stress-response, and transcription factors. To verify these results and find genes that are directly responsible for CP-r, as opposed to those reflecting a secondary response induced by cisplatin treatment or resulting from CP-r, we constructed a retroviral cDNA library in the vector pLNCX2 from KB-CP.5 (KCP.5), a cell line selected in one step after exposure to cisplatin at 0.5 microg/ml. Using a library of cDNAs (1.8 x 10(6) cDNA clones) and an intermittent cisplatin selection system to allow more effective functional cloning, 11 expressed cDNAs were identified in a primary pool of 93,000 transfected cell clones. Metallothionein 2A, a known CP-r gene, was among these 11 genes found in the transfectants after CP selection. Several other genes, including those encoding ribosomal proteins (e.g., RPL36) and heat shock protein (e.g., HSP10), were also found among the cisplatin-selected clones. Transfection of either the RPL36 cDNA or HSP10 cDNA conferred on KB-3-1 cells 2.5- to 3-fold resistance to cisplatin by clonogenic assays. A subsequent transfection also identified RPL36 as a CP-r gene. The finding that a ribosomal protein gene, RPL36, contributes to CP-r should stimulate study of the role of ribosomal proteins in multifactorial mechanisms of cisplatin resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16394183      PMCID: PMC1409811          DOI: 10.1124/mol.105.017525

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  21 in total

Review 1.  Identification of genes that mediate sensitivity to cisplatin.

Authors:  H Niedner; R Christen; X Lin; A Kondo; S B Howell
Journal:  Mol Pharmacol       Date:  2001-12       Impact factor: 4.436

2.  Upregulation of stress response mRNAs in COS-7 cells exposed to cadmium.

Authors:  Myeong Jin Lee; Hisahide Nishio; Hitoshi Ayaki; Mitsuaki Yamamoto; Kimiaki Sumino
Journal:  Toxicology       Date:  2002-05-24       Impact factor: 4.221

Review 3.  Cellular processing of platinum anticancer drugs.

Authors:  Dong Wang; Stephen J Lippard
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

4.  Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance.

Authors:  F Javier Pérez-Victoria; Francisco Gamarro; Marc Ouellette; Santiago Castanys
Journal:  J Biol Chem       Date:  2003-09-27       Impact factor: 5.157

5.  Increased calcium influx and ribosomal content correlate with resistance to endoplasmic reticulum stress-induced cell death in mutant leukemia cell lines.

Authors:  Yicheng Zhang; Stuart A Berger
Journal:  J Biol Chem       Date:  2003-12-01       Impact factor: 5.157

6.  Alteration in copy numbers of genes as a mechanism for acquired drug resistance.

Authors:  Kohichiroh Yasui; Saori Mihara; Chen Zhao; Hiroyuki Okamoto; Fumiko Saito-Ohara; Akihiro Tomida; Tadao Funato; Akira Yokomizo; Seiji Naito; Issei Imoto; Takashi Tsuruo; Johji Inazawa
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

7.  Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells.

Authors:  Yue-Xin Shan; Tsun-Jui Liu; Hou-Fen Su; Ahmad Samsamshariat; Ruben Mestril; Ping H Wang
Journal:  J Mol Cell Cardiol       Date:  2003-09       Impact factor: 5.000

8.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy.

Authors:  Hans-Guido Wendel; Elisa De Stanchina; Jordan S Fridman; Abba Malina; Sagarika Ray; Scott Kogan; Carlos Cordon-Cardo; Jerry Pelletier; Scott W Lowe
Journal:  Nature       Date:  2004-03-18       Impact factor: 49.962

9.  Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling.

Authors:  Aleksandra Mandic; Johan Hansson; Stig Linder; Maria C Shoshan
Journal:  J Biol Chem       Date:  2002-12-31       Impact factor: 5.157

10.  Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines.

Authors:  Xing-Jie Liang; Ding-Wu Shen; Susan Garfield; Michael M Gottesman
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

View more
  12 in total

1.  Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance.

Authors:  Ding-Wu Shen; Jichun Ma; Mitsunori Okabe; Guofeng Zhang; Di Xia; Michael M Gottesman
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

2.  The tumor suppressor rpl36 restrains KRAS(G12V)-induced pancreatic cancer.

Authors:  Elayne Provost; Jennifer M Bailey; Sumar Aldrugh; Shu Liu; Christine Iacobuzio-Donahue; Steven D Leach
Journal:  Zebrafish       Date:  2014-12       Impact factor: 1.985

Review 3.  Identification and validation of protein targets of bioactive small molecules.

Authors:  Denis V Titov; Jun O Liu
Journal:  Bioorg Med Chem       Date:  2011-12-20       Impact factor: 3.641

Review 4.  Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.

Authors:  Ding-Wu Shen; Lynn M Pouliot; Matthew D Hall; Michael M Gottesman
Journal:  Pharmacol Rev       Date:  2012-06-01       Impact factor: 25.468

Review 5.  Cisplatin in cancer therapy: molecular mechanisms of action.

Authors:  Shaloam Dasari; Paul Bernard Tchounwou
Journal:  Eur J Pharmacol       Date:  2014-07-21       Impact factor: 4.432

Review 6.  Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.

Authors:  Hark Kyun Kim; Jeffrey E Green
Journal:  Pharmacogenomics       Date:  2014-02       Impact factor: 2.533

7.  Lowly expressed ribosomal protein s19 in the feces of patients with colorectal cancer.

Authors:  Chih-Cheng Chien; Tien-Chien Tu; Chi-Jung Huang; Shung-Haur Yang; Chia-Long Lee
Journal:  ISRN Gastroenterol       Date:  2012-01-09

8.  Highly expressed ribosomal protein L34 indicates poor prognosis in osteosarcoma and its knockdown suppresses osteosarcoma proliferation probably through translational control.

Authors:  Shuju Luo; Jinmin Zhao; Mitra Fowdur; Kun Wang; Tenglong Jiang; Maolin He
Journal:  Sci Rep       Date:  2016-11-24       Impact factor: 4.379

9.  LncRNA PLAC2 down-regulates RPL36 expression and blocks cell cycle progression in glioma through a mechanism involving STAT1.

Authors:  Yan-Wei Hu; Chun-Min Kang; Jing-Jing Zhao; Ying Nie; Lei Zheng; Hai-Xia Li; Xin Li; Qian Wang; Yu-Rong Qiu
Journal:  J Cell Mol Med       Date:  2017-09-18       Impact factor: 5.310

10.  Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer.

Authors:  C-J Huang; C-C Chien; S-H Yang; C-C Chang; H-L Sun; Y-C Cheng; C-C Liu; S-C Lin; C-M Lin
Journal:  J Cell Mol Med       Date:  2008-02-04       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.